Drug intelligence / Profile preview

SKM-102

Development stage: Preclinical
Lead developer: Skymab Biotherapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

SKM-102 is a preclinical-stage monoclonal antibody candidate being developed by Skymab Biotherapeutics for the treatment of solid tumors. The therapeutic is designed to target G protein-coupled receptor 1 (GPCR1), a cell-surface protein belonging to the G-protein-coupled receptor superfamily. Skymab Biotherapeutics leverages its expertise in GPCR biology and antibody engineering to develop targeted oncology therapies, aiming to address difficult-to-drug targets in precision oncology.

Targets

GPR1

Beyond the preview

Go deeper on SKM-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKM-102.

Explore the full profile